248 related articles for article (PubMed ID: 11589920)
1. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?
Amenta F; Parnetti L; Gallai V; Wallin A
Mech Ageing Dev; 2001 Nov; 122(16):2025-40. PubMed ID: 11589920
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Parnetti L; Mignini F; Tomassoni D; Traini E; Amenta F
J Neurol Sci; 2007 Jun; 257(1-2):264-9. PubMed ID: 17331541
[TBL] [Abstract][Full Text] [Related]
3. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction.
Amenta F; Tayebati SK
Curr Med Chem; 2008; 15(5):488-98. PubMed ID: 18289004
[TBL] [Abstract][Full Text] [Related]
4. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies.
Amenta F; Di Tullio MA; Tomassoni D
Clin Exp Hypertens; 2002; 24(7-8):697-713. PubMed ID: 12450245
[TBL] [Abstract][Full Text] [Related]
5. Reappraising neurotransmitter-based strategies.
Möller HJ
Eur Neuropsychopharmacol; 1999 Apr; 9 Suppl 2():S53-9. PubMed ID: 10332935
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
Lemière J; Van Gool D; Dom R
Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352
[TBL] [Abstract][Full Text] [Related]
7. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
8. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats.
Tomassoni D; Catalani A; Cinque C; Di Tullio MA; Tayebati SK; Cadoni A; Nwankwo IE; Traini E; Amenta F
Curr Alzheimer Res; 2012 Jan; 9(1):120-7. PubMed ID: 22191561
[TBL] [Abstract][Full Text] [Related]
9. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?
Davis RE; Doyle PD; Carroll RT; Emmerling MR; Jaen J
Arzneimittelforschung; 1995 Mar; 45(3A):425-31. PubMed ID: 7763338
[TBL] [Abstract][Full Text] [Related]
10. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Alzheimers Dis; 2014; 42 Suppl 3():S281-8. PubMed ID: 24898643
[TBL] [Abstract][Full Text] [Related]
11. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
Maelicke A
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
[TBL] [Abstract][Full Text] [Related]
12. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent.
Traini E; Bramanti V; Amenta F
Curr Alzheimer Res; 2013 Dec; 10(10):1070-9. PubMed ID: 24156263
[TBL] [Abstract][Full Text] [Related]
13. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
14. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
Terry AV; Buccafusco JJ
J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease: Targeting the Cholinergic System.
Ferreira-Vieira TH; Guimaraes IM; Silva FR; Ribeiro FM
Curr Neuropharmacol; 2016; 14(1):101-15. PubMed ID: 26813123
[TBL] [Abstract][Full Text] [Related]
16. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update.
Weinstock M
Neurodegeneration; 1995 Dec; 4(4):349-56. PubMed ID: 8846227
[TBL] [Abstract][Full Text] [Related]
17. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease.
Fisher A
J Neurochem; 2012 Jan; 120 Suppl 1():22-33. PubMed ID: 22122190
[TBL] [Abstract][Full Text] [Related]
18. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.
Parnetti L; Amenta F; Gallai V
Mech Ageing Dev; 2001 Nov; 122(16):2041-55. PubMed ID: 11589921
[TBL] [Abstract][Full Text] [Related]
19. Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease.
Kamkwalala AR; Newhouse PA
Curr Alzheimer Res; 2017; 14(4):377-392. PubMed ID: 27697062
[TBL] [Abstract][Full Text] [Related]
20. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.
Levy ML; Cummings JL; Kahn-Rose R
Gerontology; 1999; 45 Suppl 1():15-22. PubMed ID: 9876214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
